

PERSONAL INFORMATION

Alice Indini



✉ alice.indini@gmail.com

WORK EXPERIENCE

-
- 01/02/2023- current **Medical Oncologist, Consultant**
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Italy)
Ward and outpatient activity – melanoma, phase I clinical trials
- 01/07/2021 – 31/01/2023 **Medical Oncologist, Consultant**
Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Varese (Italy)
Ward and outpatient activity – melanoma, skin tumors, thoracic tumors
- 01/11/2019 – 30/06/2021 **Medical Oncologist, Fellow**
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano (Italy)
Outpatient activity – melanoma, skin tumors, Kaposi sarcoma, thoracic tumors
- 17/09/2018 - 31/10/2019 **Medical Oncologist, Fellow**
ASST Papa Giovanni XXIII, Bergamo (Italy)
Medical Oncology Department
Outpatient activity – melanoma, skin tumors, GI tumors
- 01/05/2017–13/09/2018 **Resident**
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Italy)
Medical Oncology Department
Outpatient activity – Melanoma Oncology Unit
- 01/01/2016–30/04/2017 **Resident**
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Italy)
Medical Oncology Department
Ward and outpatient activity - Pediatric Oncology Unit
- 10/02/2014–31/12/2015 **Resident**
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Italy)
Residency in Medical Oncology Department

ward and outpatient activity - solid tumors (breast cancer, melanoma, phase I clinical trials)

08/09/2013–07/02/2014 **Resident**
 Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda, Milano (Italy)
 Residency in Medical Oncology Department
 ward activity - Internal Medicine

EDUCATION AND TRAINING

02/2022 **Scientific qualification for the functions of second-level professor in Medical Oncology**

05/09/2018 **Medical Oncology Degree**
 Final grade: 70/70
 Università Statale, Milano (Italy)

27/03/2013
 11/2012 Enrollment to Ordine dei Medici di Milano (n° 43170)
 Medical professional license, Università Statale di Milano, (Italy)

20/07/2012 **MD degree**
 Final grade: 110/110 cum laude
 Università Statale, Milano (Italy)

09/2001–06/2006 **Diploma. Major: Classical Studies**
 Final Grade: 100/100 cum laude
 Istituto Gonzaga, Milano (Italy)

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C2	C1	C1	C1
Spanish	A2	B1	A1	A1	A1

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

Digital competence

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving
Proficient user	Proficient user	Independent user	Basic user	Basic user

Professional expertise

Main areas of expertise: cutaneous tumors – melanoma; immunotherapy.

During university I attended the hospital wards of Internal Medicine, Endocrinology, Oncologic Hematology, Dermatology, Orthopedics, Neurology, Pathology of Ospedale Policlinico, Milano.

Degree in Medicine cum laude with dissertation on “Growth Hormone (GH) therapy: a retrospective study on oncologic risk in pediatric patients with brain tumors”.

During the Oncology Residency I made ward and outpatient activity both in adult oncology (melanoma, breast cancer, phase I clinical trials), and pediatric oncology (solid tumors of the pediatric age). I also had active clinical research activity with production of papers on pediatric oncology (principal areas of expertise: solid tumors, oncologic treatments sequelae in pediatric age), on melanoma and gynecologic tumors.

Degree in Medical Oncology with dissertation on “Immune checkpoint inhibitors as therapeutic strategy for advanced/metastatic melanoma: the INT experience”.

I have actively taken part to clinical phase I-III trials of pediatric and adult oncology, as sub-investigator. I am currently principal investigator in a phase II clinical trial evaluating combination treatment with pembrolizumab and lenvatinib for patients with pretreated classic Kaposi sarcoma.

Training ICG GCP R2 obtained in 2023..

Basic Life Support Defibrillation (BLSD) training on 2022; Advanced Life Support (ALS) training on 2023.

Other scientific proficiencies: Oral presentation of scientific works, both in national and international congresses. Training courses attendances.

I authored more than one hundred papers in the field of medical oncology, and 90 peer-reviewed papers indexed in PubMed, of which 37 as first author. I have 2403 citations on Google Scholar (https://scholar.google.com/citations?user=o91_FyAAAAAJ&hl=it), and 1802 on Scopus (h-index: 24).

Reviewer for: The Lancet Oncology, European Journal of Cancer, Journal for Immunotherapy if cancer, European Journal of Cancer Skin Cancer, American Journal of Clinical Oncology, Gynecologic Oncology, Cancer Group, Seminars in Cancer Biology, World Journal of Surgical Oncology, Expert Opinion on Drug Safety, British Medical Journal, International Journal of Medical Sciences, Melanoma Research, Human Vaccines and Immunotherapeutics.

Member of the Practicing Oncology Working Group (POWG), European Society of Medical Oncology (ESMO), and of the Italian Melanoma Intergroup (IMI) Young Working Group.

Other medical proficiencies: Diagnostic and therapeutic rachicenteses. Bone marrow biopsies and aspirates.

Driving licence

B

ADDITIONAL INFORMATION**Oral Presentations**

“Adjuvant and neoadjuvant therapy in melanoma: controversies and open questions”.
National Scientific Forum of Romanian Oncologists. Poiana Brasov, Romania, 2025.

“Novel approaches to immune-related toxicities”.

14th Novi Sad Oncology Congress. Novi Sad, Serbia, 2024.

“Cumulative and late onset toxicity in immunotherapy”.

ESMO Preceptorship Practising Oncology: dealing with special strategies, patient populations and toxicities. Lugano, Svizzera. 2024.

“Perioperative strategy non-melanoma skin cancers: immunotherapy, radiotherapy and surgery”.

ESMO Preceptorship Practising Oncology: dealing with special strategies, patient populations and

toxicities. Lugano, Svizzera. 2024.

“Hereditary Syndromes and Management Challenges of Secondary Tumors in Pediatric Cancer Survivors: Transitioning to Adult Oncology”.

XLIX Congresso Nazionale AIEOP. Bologna. 2024.

“Management of treatment resistance during adjuvant therapy”.

Italian Melanoma Intergroup (IMI) annual meeting. Rimini, Italy. 2024.

“Complexity of perioperative decisions in the era of novel therapies”.

European Society for Medical Oncology (ESMO). Barcelona, Spain. 2024

“YO boxing session: who should be responsible for cancer survivorship – General Practitioners”.

European Society for Medical Oncology (ESMO). Barcelona, Spain. 2024

“Challenges in the era of novel GI Cancer Treatments”.

National Scientific Forum of Romanian Oncologists. Sibiu, Romania, 2024

“Adult patients with advanced melanoma: standard treatment, early trials and current drug approvals”.

SIOPEurope 5th Annual Meeting. Milan, Italy. 2024

“More than CPIs in melanoma immunotherapy: vaccines, TILs, combos”.

Novi Sad Oncology Congress. Novi Sad, Serbia. 2024.

“Adjuvant therapy in BRAF mutant melanoma”.

Italian Melanoma Intergroup (IMI) annual meeting. Naples, Italy. 2023.

“Treatment decisions based on by biomarkers in melanoma”.

Romanian National Congress. Brasov, Romania. 2023.

“Elements to build a molecular tumor board”.

European Society for Medical Oncology (ESMO). Paris, France. 2022.

“State-of-the-art: Treatment Decisions Based on Biomarkers. Molecular Biology for Melanoma.

ESMO Preceptorship on Molecular Cancer Biology for Practising Oncologists and Cancer Treatment De-escalation. Lugano, Switzerland. 2022.

“News in the treatment of cutaneous tumors (melanoma and cutaneous squamous cell carcinoma)”.

Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) Conference 2021, FAD Live Webinar.

“Body-mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study”.

XXV Italian Melanoma Intergroup (IMI) National Congress. Bologna, Italy. 2019

“Immunotherapy in the present and in the future”.

Personalized therapies in Oncology: from chemotherapy to tailored treatments. Alzano Lombardo (BG), Italy. 2019

"Immunotherapy: reality or illusion?".

Gastrointestinal tract tumors: between science and clinical practice. VIII National workshop. Bergamo, Italy. 2019

"Immunotherapy in the present and in the future".

Twenty years of oncology in Val Serian: past, present and future. Alzano Lombardo (BG), Italy. 2018

"Long-term Experience with Whole Ventricle Irradiation (WVI) for Central Nervous System (CNS) Germinoma".

5th International CNS Germ Cell Tumors Symposium. Columbus, US. 2017

"Tumor response evaluation during immunotherapy".

Advanced Melanoma Training (TEMA). Milano, Italy. 2017

"Clinical Case: the patient with low burden of disease"

Innovative Therapies for Metastatic Melanoma (iTheme). Milano, Italy. 2017

"Osteosarcoma-osteoblastoma association: multidisciplinary management of a rare clinical entity"

Pediatric hemato-oncology training course. Riccione, Italy. 2016

Awards

2021 "Paladini Italiani della Salute" award for clinical research on COVID-19 in cancer patients.

2020 Approval of the MSD MISP drug-only concept "A Phase II single-arm study of pembrolizumab plus lenvatinib in previously treated Classic Kaposi sarcoma (CKS)".

2019 winner of the V Edition of the Award in memory of Marzia Galli Kienle – Fondazione Solidarietà in Oncologia San Marco, Zingonia. Special Award Pediatric Oncology for the paper entitled "Long-term safety of growth hormone replacement therapy after childhood medulloblastoma and PNET: it is time to set aside old concerns".

Papers

"Melanoma in children and adolescents: Distinct biology, evolving therapies, and unmet needs".

Indini A, Chiaravalli S, Bergamaschi L, Casanova M, Del Vecchio M, Massimino M, Ferrari A. Tumori. 2025 May 24;3008916251341676. doi: 10.1177/03008916251341676.

"From walls to wonder: Talking about spaces tailored for adolescents and young adults with cancer".

Clerici CA, Scotti F, Pagani Bagliacca E, Rossi S, Patriccioli A, Quarello P, Toss A, Mascarini M, Maruzzo M, Lambertini M, Incorvaia L, Milano GM, Zucchetti G, Tomesello A, Spinelli M, Puccini A, Bertuzzi AF, Indini A, Perillo T, Baldi GG, Razzaboni E, Colombo C, Marziali L, Massimino M, Peccatori FA, Ferrari A.

Tumori. 2025 Apr 15;3008916251330771. doi: 10.1177/03008916251330771.

"Dabrafenib and Trametinib for the Treatment of Pediatric and Adolescent Melanoma: Single Center Experience Data From Italian Compassionate Use".

Chiaravalli S, Indini A, Del Vecchio M, Casanova M, Massimino M, Bergamaschi L, Ferrari A. Pediatr Blood Cancer. 2025;72(5):e31644. doi: 10.1002/pbc.31644.

"Incidence and prognosis of cutaneous melanoma in European adolescents and young adults (AYAs): EURO CARE-6 retrospective cohort results."

Indini A, Didoné F, Massi D, Puig S, Casadevall JR, Bennett D, Katalinic A, Sanvisens A, Ferrari A, Lasalvia P, Demuru E, Ragusa R, Mayer-da-Silva A, Blum M, Mousavi M, Kuehni C,

Mihor A, Mandalà M, Trama A; EUROCARE-6 Working Group.
Eur J Cancer. 2024; 213: 115079. doi: 10.1016/j.ejca.2024.115079.

“Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)”.

Mandalà M, Ferrari A, Brecht IB, Suijkerbuijk KP, Maschke L, Giannarelli D, Indini A, Ubaldi M, Pecci G, Atkinson V, Helgadottir H, Chiaravalli S, Benannoune N, Robert C, Teterycz P, Rutkowski P, Puig S, Madonna G, Kebudi R, Grynberg S, Arantes LM, Bien E, Krawczyk M, Pasquale MD, Dierselhuis MP, Massi D, Long GV, Ascierto PA, Eggermont AMM; Melcaya consortium (see appendix for the list of the coauthors belonging to the Melcaya Consortium).
Eur J Cancer. 2024;211:114305. doi: 10.1016/j.ejca.2024.114305. Epub 2024 Sep 3. PMID: 39236557.

“Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma”.

Indini A, Gueli R, Cerati M, Rijavec E, Parravicini M, Casagrande S, Rovelli C, Grossi PA, Grossi F. Melanoma Res. 2024;34:386-389. doi: 10.1097/CMR.0000000000000981.

“Melanoma and sex hormones: Pathogenesis, progressive disease and response to treatments”.

Tagliatalata I, Indini A, Santanelli G, Di Liberti G, Di Guardo L, De Braud F, Del Vecchio M. Tumori. 2024 Feb 19:3008916241231687. doi: 10.1177/03008916241231687.

“Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study”.

Mandalà M, Lorigan P, Sergi MC, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Tucci M, Guida M, Spagnolo F, Rossi E, Occeili M, Queirolo P, Quaglino P, Depenni R, Merelli B, Placzke J, Di Giacomo AM, Del Vecchio M, Indini A, da Silva IP, Menzies AM, Long GV, Robert C, Rutkowski P, Ascierto PA. Eur J Cancer. 2024; 199:113542. doi: 10.1016/j.ejca.2024.113542.

“Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center”.

Denaro N, Passoni E, Indini A, Nazzaro G, Beltramini GA, Benzecry V, Colombo G, Cauchi C, Solinas C, Scartozzi M, Marzano AV, Garrone O. Vaccines (Basel). 2023 Sep 18;11(9):1500. doi: 10.3390/vaccines11091500.

“Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup”.

Rubatto M, Fava P, Stanganelli I, Ribero S, Pigozzo J, Di Giacomo AM, Ridolfi L, Tronconi MC, Trojaniello C, Bersanelli M, Garutti M, Indini A, De Risi I, De Tursi M, Merelli B, Morgese F, Occeili M, Cappellini GCA, Poletto S, Fedele D, Brugnara S, Frisinghelli M, Formisano L, Conca R, Tucci M, Russillo M, Ceroni L, Queirolo P, Targato G, Strippoli S, Mandalà M, Guida M, Quaglino P. Eur J Cancer. 2023 Jul;187:25-35. doi: 10.1016/j.ejca.2023.03.020.

“Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study”.

Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Veccia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA, Aerts JGJV, Berardi R. J Natl Cancer Inst. 2023 Jul 6;115(7):796-804. doi: 10.1093/jnci/djad061.

“ Twelve ESMO Congress 2022 breakthroughs: practicing oncologists' perceptions and potential application on presented data”.

van Halteren HK, Bennouna J, Brasiuniene B, Tomas AJC, Trinidad AMG, Indini A, Liposits G, Pellegrino B, Popovic L, Tan A, Vidra R, Strijbos M; Practising Oncologists Working Group. ESMO Open. 2023; 8: 100773. doi: 10.1016/j.esmoop.2022.100773.

“Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries”.

NIHR Global Health Unit on Global Surgery; COVIDSurg Collaborative.

Lancet. 2022; 400: 1607-1617. doi: 10.1016/S0140-6736(22)01846-3.

“Pathology of Immunotherapy-induced Responses in Cutaneous Melanoma: Current Evidences and Future Perspectives”.

Indini A, Lombardo M, Sidoni A, Gianatti A, Mandalà M, Massi D.
Adv Anat Pathol. 2022 Oct 5. doi: 10.1097/PAP.0000000000000375.

“NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets”.

Indini A, Fiorilla I, Ponzone L, Calautti E, Audrito V.
Int J Mol Sci. 2022; 23:9985. doi: 10.3390/ijms23179985.

“Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges”.

Indini A, Massi D, Pirro M, Roila F, Grossi F, Sahebkar A, Glodde N, Bald T, Mandalà M.
Semin Cancer Biol. 2022; 86:477-490. doi: 10.1016/j.semcancer.2022.06.005.

“Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study”.

Dimitriou F, Namikawa K, Reijers ILM, Buchbinder EI, Soon JA, Zaremba A, Teterycz P, Mooradian MJ, Armstrong E, Nakamura Y, Vitale MG, Tran LE, Bai X, Allayous C, Provent-Roy S, Indini A, Bhave P, Farid M, Kähler KC, Mehmi I, Atkinson V, Klein O, Stonesifer CJ, Zaman F, Haydon A, Carvajal RD, Hamid O, Dummer R, Hauschild A, Carlino MS, Mandala M, Robert C, Lebbe C, Guo J, Johnson DB, Ascierto PA, Shoushtari AN, Sullivan RJ, Cybulska-Stopa B, Rutkowski P, Zimmer L, Sandhu S, Blank CU, Lo SN, Menzies AM, Long GV.
Ann Oncol. 2022;33:968-980. doi: 10.1016/j.annonc.2022.06.004.

“BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer”.

Bogani G, Chiappa V, Bini M, Ronzulli D, Indini A, Conca E, Raspagliesi F. Tumori. 2022 Mar 20:3008916211073621. doi: 10.1177/03008916211073621. Epub ahead of print. PMID: 35311394.

“Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario”.

Cantini L, Mentrasti G, Russo GL, Signorelli D, Pasello G, Rijavec E, Russano M, Antonuzzo L, Rocco D, Giusti R, Adamo V, Genova C, Tuzi A, Morabito A, Gori S, Verde NL, Chiari R, Cortellini A, Cognigni V, Pecci F, Indini A, De Toma A, Zattarin E, Oresti S, Pizzutilo EG, Frega S, Erbetta E, Galletti A, Citarella F, Fancelli S, Caliman E, Della Gravara L, Malapelle U, Filetti M, Piras M, Toscano G, Zullo L, De Tursi M, Di Marino P, D'Emilio V, Cona MS, Guida A, Caglio A, Salerno F, Spinelli G, Bennati C, Morgillo F, Russo A, Dellepiane C, Vallini I, Sforza V, Inno A, Rastelli F, Tassi V, Nicolardi L, Pensieri V, Emili R, Roca E, Migliore A, Galassi T, Rocchi MLB, Berardi R. ESMO Open. 2022;7(2):100406. doi: 10.1016/j.esmoop.2022.100406. Epub ahead of print. Erratum in: ESMO Open. 2022 Apr 1;7(2):100471. PMID: 35219245; PMCID: PMC8810307.

“Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib”.

Rijavec E, Biello F, Indini A, Grossi F, Genova C. Clin Pharmacol. 2022;14:1-9. doi: 10.2147/CPAA.S284850. PMID: 35082536; PMCID: PMC8786362.

“Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: a Comprehensive Review”.

Indini A, Roila F, Grossi F, Massi D, Mandalà M. Int. J. Mol. Sci. 2022, 23, 147.
<https://doi.org/10.3390/ijms23010147>.

“Factors predicting morbidity in surgically-staged high-risk endometrial cancer patients”.

Bogani G, Papadia A, Buda A, Casarin J, Di Donato V, Plotti F, Gasparri ML, Cimmino C, Pinelli C, Perrone AM, Barra F, Cromi A, Di Martino G, Palaia I, Ferrero S, Indini A, De Iaco P, Angioli R, Luvero D, Muzii L, Ghezzi F, Landoni F, Mueller MD, Benedetti Panici P, Raspagliesi F. Eur J Obstet Gynecol Reprod Biol. 2021;266:169-174. doi: 10.1016/j.ejogrb.2021.09.029. PMID: 34688098.

“Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer”.

Rijavec E, Genova C, Biello F, Rossi G, Indini A, Grossi F.
Expert Rev Respir Med. 2021;15:1427-1435. doi: 10.1080/17476348.2021.1987887. PMID: 34590937.

” Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies”.

Tomasello G, Ghidini M, Ghidini A, Trevisan F, Celotti A, Russo A, Gambini D, Indini A, Rijavec E, Bareggi C, Galassi B, Petrelli F. Radiother Oncol. 2021;164:13-19. doi: 10.1016/j.radonc.2021.09.001. PMID: 34509562.

“COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report”.

Indini A, Costa S, Ierardi AM, Rijavec E, Passoni E, Grossi F.
Melanoma Res. 2021; 31: 490-493. doi: 10.1097/CMR.0000000000000768. PMID: 34433198.

“Metabolic disorders and the risk of cholangiocarcinoma”.

Ghidini M, Ramai D, Facciorusso A, Singh J, Tai W, Rijavec E, Galassi B, Grossi F, Indini A.
Expert Rev Gastroenterol Hepatol. 2021;15:999-1007. doi: 10.1080/17474124.2021.1946393. PMID: 34423721.

“Cancer mechanisms and emerging therapies”.

Gulei D, Indini A, Jerônimo C, Iuga C-A, Grossi F.
Pharmaceutics. 2021; 13(7): 1045.

“COVID-19 Vaccination in Patients with Classic Kaposi's Sarcoma”.

Indini A, Turlaki A, Grossi F, Gambini D, Brambilla L.
Vaccines (Basel). 2021; 9: 632. doi: 10.3390/vaccines9060632.

“Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations”.

Ferrari A, Lopez Almaraz R, Reguerre Y, Cesen M, Bergamaschi L, Indini A, Schneider DT, Godzinski J, Bien E, Stachowicz-Stencel T, Eigentler TK, Chiaravalli S, Krawczyk MA, Pappo A, Orbach D, Bisogno G, Brecht IB.
Pediatr Blood Cancer. 2021; 68 Suppl 4:e28992. doi: 10.1002/pbc.28992.

“Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications”.

Indini A, Grossi F, Mandalà M, Taverna D, Audrito V.
Biomedicines. 2021; 9: 607.

“Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?”

Indini A, Roila F, Grossi F, Massi D, Mandalà M.
Am J Clin Dermatol. 2021 May 25. doi: 10.1007/s40257-021-00608-5.

“Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors”.

Indini A, Rijavec E, Ghidini M, Cortellini A, Grossi F.
Pharmaceutics. 2021; 13: 653.

“Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors”.

Indini A, Rijavec E, Grossi F.
Int J Mol Sci. 2021; 22(9): 4774.

“Uterine serous carcinoma”.

Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Pòka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ.
Gynecol Oncol. 2021.

“Circulating Biomarker of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review”.

Indini A, Rijavec E, Grossi F.
Cancers (Basel). 2021; 13(8): 1794.

“Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer”.

Indini A, Nigro O, Lengyel CG, Ghidini M, Petrillo A, Lopez S, Raspagliesi F, Trapani D, Khakoo S, Bogani G.
Cancers (Basel). 2021; 13(7): 1663.

“Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial”.

Indini A, Grossi F.
Lancet Oncol. 2021; 22(5): 573-575.

“Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with amelanotic melanoma: the experience of 11 Italian centres”.

Bonacina R, Indini A, Massazza G, Rulli E, Gianatti A, Mandalà M; Amelanotic Melanoma Cooperative Group.
J Clin Pathol. 2021; jclinpath-2021-207527.

“The appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a Risk Prognostic Score”.

Ghidini M, Indini A, Rijavec E, Bareggi C, Cattaneo M, Tomasello G, Galassi B, Gambini D, Grossi F.
Viruses 2021; 13(3): 508.

“Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review”.

Indini A, Rijavec E, Ghidini M, Tomasello G, Cattaneo M, Barbin F, Bareggi C, Galassi B, Gambini D, Grossi F.
Int J Mol Sci. 2021; 22: 2628.

“Association of Obesity with Survival Outcomes in Patients with Cancer: a Systematic Review and Meta-Analysis”.

Petrelli F, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, Salati M, Dottorini L, Iaculli A, Varricchio A, Rampulla V, Barni S, Cabiddu M, Bossi A, Ghidini A, Zaniboni A.
JAMA Netw Open. 2021; 4(3): e213520.

“Management of patients with cancer during the the COVID-19 pandemic: the Italian perspective on the second wave”.

Indini A, Pinotti G, Artioli F, Aschele C, Bernardi D, Butera A, Defraia E, Fasola G, Gamucci T, Giordano M, Iaria A, Leo S, Ribecco AS, Rossetti R, Savastano C, Schena M, Silva RR, Grossi F, Blasi L.
Eur J Cancer. 2021; 148: 112-116.

“Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC”.

Rijavec E, Indini A, Ghidini M, Tomasello G, Cattaneo M, Barbin F, Grossi F.
Expert Rev Anticancer Ther. 2021: 1-9.

“A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday”.

Indini A, Rijavec E, Mandalà M, Castiglioni S, Beltramo G, Grossi F.
Melanoma Res. 2021 Feb 18. doi: 10.1097/CMR.0000000000000725.

“Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars”.

Ghidini M, Indini A, Nigro O, Polito S, Rijavec E, Petrelli F, Tomasello G.
Expert Opin Pharmacother. 2021:1-9. doi: 10.1080/14656566.2021.1873950.

“Triage process for the assessment of coronavirus disease 2019-positive patients with cancer: The ONCOVID prospective study”.

Indini A, Cattaneo M, Ghidini M, Rijavec E, Bareggi C, Galassi B, Gambini D, Ceriani R, Ceriotti F,

Berti E, Grossi F.

Cancer. 2020 Dec 3. doi: 10.1002/cncr.33366. Epub ahead of print. PMID: 33270908.

“Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study”.

Rutkowski P, Indini A, De Luca M, Merelli B, Mariuk-Jarema A, Teterycz P, Rogala P, Lugowska I, Cybulska-Stopa B, Labianca A, Di Guardo L, Del Vecchio M, Pigozzo J, Randon G, Corti F, Tondini CA, Rulli E, Mandala M.

J Immunother Cancer. 2020;8(2):e001117. doi: 10.1136/jitc-2020-001117.

“Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy”.

Teterycz P, Czarna AM, Indini A, Spatek MJ, Labianca A, Rogala P, Cybulska-Stopa B, Quagliano P, Ricardi U, Badellino S, Szumera-Ciećkiewicz A, Falkowski S, Mandala M, Rutkowski P.

Cancers (Basel). 2020;12(11):3131. doi: 10.3390/cancers12113131.

“An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival”.

Mannavola F, Mandala M, Todisco A, Sileni VC, Palla M, Minisini AM, Pala L, Morgese F, Di Guardo L, Stucci LS, Guida M, Indini A, Quagliano P, Ferraresi V, Marconcini R, Tronconi MC, Rossi E, Nigro O, Occeci M, Cortellini A, Quadrini S, Palmieri G, Pigozzo J, Ascierto PA, Vitale MG, Strippoli S, Ferrucci PF, Berardi R, Randon G, Cardone P, Schinzari G, Silvestris F, Tucci M.

Front Oncol. 2020;10:1652. doi: 10.3389/fonc.2020.01652.

“Letter of response to comments on: Developing a risk assessment score for patients with cancer during COVID-19 pandemic: A war on two fronts”.

Indini A, Rijavec E, Ghidini M, Cattaneo M, Grossi F.

Eur J Cancer. 2020;140:161-162. doi: 10.1016/j.ejca.2020.09.003.

“A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic”.

Zaniboni A, Ghidini M, Grossi F, Indini A, Trevisan F, Iaculli A, Dottorini L, Moleri G, Russo A, Vavassori I, Brevi A, Rausa E, Boni L, Dondossola D, Valeri N, Ghidini A, Tomasello G, Petrelli F.

Cancers (Basel). 2020;12(9):2452. doi: 10.3390/cancers12092452.

“Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients”.

Indini A, Mandalà M.

Expert Opin Drug Saf. 2020;19(10):1229-1236. doi: 10.1080/14740338.2020.1817376.

“Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer”.

Labianca A, Bosetti T, Indini A, Negrini G, Labianca RF.

Cancers (Basel). 2020;12(8):2070. doi: 10.3390/cancers12082070.

“Coronavirus infection and immune system: An insight of COVID-19 in cancer patients”.

Indini A, Rijavec E, Ghidini M, Bareggi C, Cattaneo M, Galassi B, Gambini D, Grossi F.

Crit Rev Oncol Hematol. 2020 Sep;153:103059. doi: 10.1016/j.critrevonc.2020.103059.

“Novel treatment strategies for early-stage lung cancer: the oncologist's perspective”.

Indini A, Rijavec E, Bareggi C, Grossi F.

J Thorac Dis. 2020;12(6):3390-3398. doi: 10.21037/jtd.2020.02.46.

“Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic”.

Indini A, Rijavec E, Ghidini M, Cattaneo M, Grossi F.

Eur J Cancer. 2020;135:47-50. doi: 10.1016/j.ejca.2020.05.017.

“Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study”.

Parisi A, Cortellini A, Cannita K, Venditti O, Camarda F, Calegari MA, Salvatore L, Tortora G, Rossini D, Germani MM, Boccaccino A, Dell'Aquila E, Fulgenzi C, Santini D, Tursi M, Tinari N, Marino PD, Lombardi P, Keränen SR, Álvaro MH, Zurlo IV, Corsi DC, Emiliani A, Zanaletti N, Troiani T, Vitale P, Giampieri R, Merloni F, Occhipinti MA, Marchetti P, Roberto M, Mazzuca F, Ghidini M, Indini A, Garajova I, Zoratto F, Monache SD, Porzio G, Ficorella C.

Cancers (Basel). 2020;12(5):1259. doi: 10.3390/cancers12051259.

“Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis”.

Indini A, Petrelli F, Tomasello G, Rijavec E, Facciorusso A, Grossi F, Ghidini M.

Cancers (Basel). 2020;12(4):998. doi: 10.3390/cancers12040998.

“Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey”.

Indini A, Aschele C, Cavanna L, Clerico M, Daniele B, Fiorentini G, Fioretto L, Giordano M, Montesarchio V, Ortega C, Pinotti G, Scanni A, Zamagni C, Blasi L, Grossi F.

Eur J Cancer. 2020;132:17-23. doi: 10.1016/j.ejca.2020.03.024.

“The prognostic impact of the extent of ulceration in patients with clinical stage I-II melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI)”.

Portelli F, Galli F, Cattaneo L, Cossa M, De Giorgi V, Forte G, Fraternali Orcioni G, Gianatti A, Indini A, Labianca A, Maurichi A, Merelli B, Montesco MC, Occelli M, Patuzzo R, Piazzalunga D, Pigozzo J, Quaglino P, Ribero S, Salvatori R, Saraggi D, Sena P, Senetta R, Valeri B, Tanaka M, Fukayama M, Palmieri G, Mandalà M, Massi D; Italian Melanoma Intergroup (IMI).

Br J Dermatol. 2020 Apr 13. doi: 10.1111/bjd.19120.

“Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer”.

Indini A, Rijavec E, Ghidini M, Bareggi C, Gambini D, Galassi B, Antonelli P, Bettio G, Di Nubila C, Grossi F.

Expert Opin Pharmacother. 2020;21(8):931-940. doi: 10.1080/14656566.2020.1738387.

“A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy”.

Indini A, Sessa M, Merelli B, Foresti C, Mandalà M.

Eur J Cancer. 2020;129:1-3. doi: 10.1016/j.ejca.2020.01.009.

“Immune related adverse events and response to immunotherapy: Focus on corticosteroids”.

Indini A, Rijavec E, Grossi F.

Lung Cancer. 2020;145:225. doi: 10.1016/j.lungcan.2020.02.009.

“Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience”.

Indini A, Di Guardo L, Cimminiello C, Lorusso D, Raspagliesi F, Del Vecchio M.

J Gynecol Oncol. 2019;30(6):e94. doi: 10.3802/jgo.2019.30.e94.

“Advances in Laparoscopic Surgery for Cervical Cancer”.

Bogani G, Leone Roberti Maggiore U, Rossetti D, Ditto A, Martinelli F, Chiappa V, Ferla S, Indini A, Sabatucci I, Lorusso D, Raspagliesi F.

Crit Rev Oncol Hematol. 2019 Nov;143:76-80. doi: 10.1016/j.critrevonc.2019.07.021. Epub 2019 Aug 2. Erratum in: Crit Rev Oncol Hematol. 2020 Jan;145:102833.

“Artificial Intelligence Estimates the Importance of Baseline Factors in Predicting Response to Anti-PD1 in Metastatic Melanoma”.

Indini A, Di Guardo L, Cimminiello C, De Braud F, Del Vecchio M.

Am J Clin Oncol. 2019; 42: 643-648

“Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma”.

Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M.

Tumori. 2019 Aug 26:300891619868009

“Adjuvant treatment of melanoma: recent developments and future perspectives”.

Testori AAE, Ribero A, Indini A, Mandalà M.

Am J Clin Dermatol. 2019 Jun 8

“Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival”.

Indini A, Tondini CA, Mandalà M.

Future Oncol. 2019; 15: 967-977

“Immune-related adverse events correlate with improved survivals in patients undergoing anti-PD1 immunotherapy for metastatic melanoma”.

Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M.

J Cancer Res Clin Oncol. 2019; 145:511-521

“Pembrolizumab in the treatment of advanced/metastatic melanoma: a single center institution experience.”

Cimminiello C, Indini A, Di Guardo L, Prisciandaro M, Randon G, Tolomio E, De Braud F, Del Vecchio M.

Melanoma Res. 2018; 29: 289-294

“Cutaneous melanoma in adolescents and young adults”.

Indini A, Brecht I, Del Vecchio M, Sultan I, Signoroni S, Ferrari A.

Pediatr Blood Cancer. 2018;65(11): e27292

“Gastrointestinal tract carcinoma in pediatric and adolescent age: the Italian TREP project experience”

Indini A, Bisogno G, Cecchetto G, Vitellaro M, Signoroni S, Massimino M, Riccipettoni G, Zecca M, Dall'Igna P, De Pasquale MD, Inserra A, Chiaravalli S, Basso E, Virgone C, Sorbara S, Di Bartolomeo M, D'Angelo P, Ferrari A.

Pediatr Blood Cancer. 2017;64(12)

“Incidental ameloblastoma diagnosed after treatment for childhood tumor”

Indini A, Luksch R, Patriarca C, Petracco G, Ronchi P, Colombo L, Massimino M.
Journal of Pediatric Surgery Case Reports. 2017; 23: 50-52

"Minimally Invasive Surgical Staging in Early-stage Ovarian Carcinoma: A Systematic Review and Meta-analysis"

Bogani G, Borghi C, Leone Roberti Maggiore U, Ditto A, Signorelli M, Martinelli F, Chiappa V, Lopez C, Sabatucci I, Scaffa C, Indini A, Ferrero S, Lorusso D, Raspagliesi F.

J Minim Invasive Gynecol. 2017; 24:552-562

"The association of pre-treatment HPV subtypes with recurrence of VIN".

Bogani G, Martinelli F, Ditto A, Signorelli M, Taverna F, Lombardo C, Chiappa V, Leone Roberti Maggiore U, Recalcati D, Scaffa C, Perotto S, Sabatucci I, Indini A, Lorusso D, Raspagliesi F.

Eur J Obstet Gynecol Reprod Biol. 2017; 211:37-41

"Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery".

Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Lopez C, Indini A, Leone Roberti Maggiore U, Sabatucci I, Lorusso D, Raspagliesi F.

Int J Gynecol Cancer. 2017; 27:514-522

"Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia".

Bogani G, Martinelli F, Ditto A, Taverna F, Lombardo C, Signorelli M, Chiappa V, Leone Roberti Maggiore U, Fontanella C, Sabatucci I, Borghi C, Recalcati D, Indini A, Lorusso D, Raspagliesi F.

Eur J Obstet Gynecol Reprod Biol 2016;23; 210:157-165

"Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer".

Bogani G, Sabatucci I, Maltese G, Lecce F, Signorelli M, Martinelli F, Chiappa V, Indini A, Leone Roberti Maggiore U, Borghi C, Fucà G, Ditto A, Raspagliesi F, Lorusso D.

Eur J Obstet Gynecol Reprod Biol 2017; 208:41-45

"Long-term safety of growth hormone replacement therapy after childhood medulloblastoma and PNET: it is time to set aside old concerns".

Indini A, Schiavello E, Biassoni V, Bergamaschi L, Magni MC, Puma N, Chiaravalli S, Pallotti F, Seregni E, Diletto B, Pecori E, Gandola L, Poggi G, Massimino M.

J Neurooncol. 2017; 131:349-357

"Measuring the efficacy of a project for adolescents and Young adults with cancer: A study from the Milan Youth Project".

Ferrari A, Silva M, Veneroni L, Magni C, Clerici CA, Meazza C, Terenziani M, Spreafico F, Chiaravalli S, Casanova M, Luksch R, Catania S, Schiavello E, Biassoni V, Podda M, Bergamaschi L, Puma N, Indini A, Proserpio T, Massimino M.

Pediatr Blood Cancer. 2016; 63:2197-2204

"Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery".

Ditto A, Bogani G, Martinelli F, Signorelli M, Chiappa V, Scaffa C, Indini A, Leone Roberti Maggiore U, Lorusso D, Raspagliesi F.

J Minim Invasive Gynecol. 2017; 24:98-102

"How do the results of the RADIANT trials impact on the management of NET patients? A systematic

review of published studies".

Pusceddu S, De Braud F, Lo Russo G, Concas L, Femia D, Vernieri C, Indini A, Formisano B, Buzzoni R.

Oncotarget. 2016; 7:44841-44847

"Surgical Management and Prognostic Factors of Vulvovaginal Melanoma".

Ditto A, Bogani G, Martinelli F, Di Donato V, Laufer J, Scasso S, Chiappa V, Signorelli M, Indini A, Lorusso D, Raspagliesi F.

J Low Genit Tract Dis. 2016;20(3):e24-9

"Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio".

Indini A, Di Nicola M, Del Vecchio M, De Braud F. J Clin Oncol. 2016; 34: 1017-8

"Morcellation of undiagnosed uterine sarcoma: A critical review".

Bogani G, Chiappa V, Ditto A, Martinelli F, Donfrancesco C, Indini A, Lorusso D, Raspagliesi F.

Crit Rev Oncol Hematol. 2016; 98:302-8

"Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma: A Systematic Review and Meta-analysis".

Bogani G, Ditto A, Martinelli F, Lorusso D, Chiappa V, Donfrancesco C, Di Donato V, Indini A, Aletti G, Raspagliesi F.

Int J Gynecol Cancer. 2016; 26:371-80

"Everolimus treatment in advanced solid tumors: a personal view".

Pusceddu S, Indini A, Procopio G.

Future Sci OA. 2015;1(3): FSO3

"Medulloblastoma treatment in a child on dialysis".

Puma N, Biassoni V, Gandola L, Pecori E, Ardissino G, Paglialonga F, Indini A, Antonelli M, Massimino M.

CNS Oncol. 2014; 3:31-6

"Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience".

Massimino M, Casanova M, Polastri D, Biassoni V, Modena P, Pecori E, Schiavello E, De Pava MV, Indini A, Rampini P, Bauer D, Catania S, Podda M, Gandola L.

Childs Nerv Syst. 2013; 29:1107-12

"EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation".

Antonicevich A, Cafarotti S, Indini A, Galli A, Russo A, Cesario A, Lococo FM, Russo P, Mainini AF, Bonifati LG, Nosotti M, Santambrogio L, Margaritora S, Granone PM, Dutly AE.

Int J Med Sci. 2013; 10:320-30

Book chapters

Indini A, Rijavec E. State of the art in the immunotherapy management of skin, thoracic and head and neck cancers. Management of immune-related adverse events. Springer Healthcare. 2022.

Indini A, Grossi F. Management of immune-related adverse events. Management of immune-related adverse events. Springer Healthcare. 2022.

Indini A, Pappo AS, Eigentler TK, Collini P, Ferrari A. Cutaneous Melanoma. Rare Tumors in Children

and Adolescents. Springer. 2022.

Indini A, Mandalà M. Pembrolizumab in Melanoma: from Care to Cure. Springer Nature. 2020

Indini A, Di Giacomo AM, Quagliano P, Mandalà M. Target therapy in advanced melanoma. The treatment of melanoma. Minerva Medica. 2019

Biassoni V, Schiavello E, Gandola L, Seregini E, Indini A, Spreafico F, Massimino M. Outcome and long-term complications. The Medulloblastoma Book. Nova Science Publishers, Inc. 2014.

Abstracts

“Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)”.

Mandalà M, Ferrari A, Brecht I, Suijkerbuijk K, Maschke L, Giannarelli D, Indini A, Ubaldi M, Atkinson VG, Helgadottir H, Chiaravalli S, De Pasquale MD, Benannoune N, Robert R, Kosela Paterczyk HM, Puig Sarda S, Massi D, Long GV, Ascierto PA, Eggermont AMM.

European Society for Medical Oncology (ESMO) 2024 Congress.

“Survival of patients with obesity and cancer: a systematic review and meta-analysis”.

Petrelli F, Ghidini A, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, Salati M, Dottorini L, Iaculli A, Varricchio A, Costanzo A, Rampulla V, Bossi A, Barni S, Zaniboni A. XXII Congresso Nazionale Associazione Italiana di Oncologia Medica (AIOM).

“The appropriateness of invasive ventilation in COVID-19 positive cancer patients: the hardest decision for oncologists”.

Ghidini M, Indini A, Rijavec E, Bareggi C, Cattaneo M, Galassi B, Gambini D, Grossi F. Poster Session, XXII Congresso Nazionale Associazione Italiana di Oncologia Medica (AIOM).

“Incidence of influenza-like illness (ILI) in cancer patients during COVID-19: the ONCOVID prospective observational study”.

Cattaneo M, Indini A, Ghidini M, Rijavec E, Bareggi C, Galassi B, Gambini D, Berti E, Grossi F.

Poster Session, XXII Congresso Nazionale Associazione Italiana di Oncologia Medica (AIOM).

“Developing a risk assessment score for cancer patients during COVID-19 pandemic”.

Indini A, Cattaneo M, Ghidini M, Rijavec E, Bareggi C, Galassi B, Gambini D, Grossi F.

Poster Session, XXII Congresso Nazionale Associazione Italiana di Oncologia Medica (AIOM).

“The appropriateness of invasive ventilation in COVID-19 positive cancer patients: the hardest decision for oncologists”.

Ghidini M, Indini A, Rijavec E, Bareggi C, Cattaneo M, Galassi B, Gambini D, Grossi F.

European Society for Medical Oncology (ESMO) 2020 virtual meeting.

“Developing a risk assessment score for cancer patients during COVID-19 pandemic”.

Indini A, Cattaneo M, Ghidini M, Rijavec E, Bareggi C, Galassi B, Gambini D, Grossi F.

Poster Session, European Society for Medical Oncology (ESMO) 2020 virtual meeting.

“Incidence of influenza-like illness (ILI) in cancer patients during COVID-19: the ONCOVID prospective observational study”.

Grossi F, Cattaneo M, Rijavec E, Ghidini M, Bareggi C, Galassi B, Gambini D, Berti E, Indini A.

Poster Session, European Society for Medical Oncology (ESMO) 2020 virtual meeting.

“Body-mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study”.

Indini A, Rutkowski P, Di Guardo L, Merelli B, Labianca A, De Luca M, Del Vecchio M, Tondini CA, Pigozzo J, Rulli E, Mandalà M.

Oral Communication. XXV Italian Melanoma Intergroup (IMI) National Congress, Bologna, Italia. 2019

“Potential impact of the introduction of nonavalent human papillomavirus vaccination: analysis of 13.665 women over a 18-year period”

Bogani G, Morano F, Indini A, Chiappa V, Lorusso D, Martinelli F, Leone Roberti Maggiore U, Ditto A, Raspagliesi F.

Oral Presentation in Plenary Session. XX National Congress Associazione Italiana di Oncologia Medica (AIOM). Roma, Italia. 2018

“Clinical predictive factors for efficacy of anti-PD1 used in first line in metastatic melanoma: an Italian Melanoma Intergroup study”.

Marconcini R, Tanda E, Di Guardo LA, Nigro O, Fava P, Stucci LS, Morgese F, Cortellini A, Stroppa E, Gallizzi G, Festino L, Grego E, Nuzzo A, Manacorda S, Bloise F, Orlandini C, Indini A, Astrua C, Falcone A.

Melanoma and skin cancers AIOM Award 2018. XX National Congress Associazione Italiana di Oncologia Medica (AIOM). Roma, Italia. 2018

“Immune-related adverse events correlate with improved survivals in patients undergoing anti-PD1 immunotherapy for metastatic melanoma”.

Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M.

Poster Session, XX National Congress Associazione Italiana di Oncologia Medica (AIOM). Roma, Italia. 2018

“Baseline predictive factors for efficacy of anti-PD1 used in first line in melanoma patients: an Italian melanoma intergroup study”.

Marconcini R, Tanda E, Di Guardo LA, Nigro O, Fava P, Todisco A, Morgese F, Cortellini A, Stroppa E, Gallizzi G, Festino L, Grego E, Quadri A, Orlandini C, Nuzzo A, Manacorda S, Bloise F, Indini A, Astrua C, Falcone A.

Poster Session, European Society for Medical Oncology (ESMO) 2018 meeting. Munich, Germany 2018

“Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?”

Farè E, Sdao S, Damian S, Cresta S, Del Vecchio M, Di Bartolomeo M, Di Guardo L, Duca M, Indini A, Necchi A, Nigro M, Prisciandaro M, Procopio G, Raggi D, Verzoni E, Pruneri G, Di Nicola M, de Braud F.

Poster Session, European Society for Medical Oncology (ESMO) 2018 meeting. Munich, Germany 2018

“Is “hyper-progression” a relevant clinical item for patients with solid tumours candidate to check-point inhibitor treatment?”

De Braud F, Di Nicola M, Damian S, Cresta S, Duca M, Indini A, Di Bartolomeo M, Galli G, Farè E, Verzoni E.

16th International Congress on Targeted Anticancer Therapies (TAT 2018). Paris, France. 2018

“Potential Implication on the Introduction of the Nonavalent Vaccination against HPV: an analysis HPV prevalence in 13.665 patients over an 18-year study period”.

Bogani G, Signorelli M, Ditto A, Martinelli F, Chiappa V, Indini A, Lorusso D, Raspagliesi F.

18th World Congress Gynecological Endocrinology. Firenze, Italia. 2018

“Long-Term Efficacy of Thyroid-Stimulating-Hormone (TSH)-Suppression during Radiotherapy

(RT) for Medulloblastoma (MBL) and Hodgkin Lymphoma (HL)".

Massimino M, Gandola L, Podda M, Spreafico F, Biassoni V, Pecori E, Schiavello E, Indini A, Diletto B, Casanova M, Ferrari A, Luksch R, Mezza C, Puma N, Chiaravalli S, Seregni E, Bergamaschi L, Pallotti F, Morosi C, Terenziani M.

49th Congress of the International Society of Pediatric Oncology (SIOP). Washington, US. 2017

"Long-term Experience with Whole Ventricle Irradiation (WVI) for Central Nervous System (CNS) Germinoma".

Indini A, Biassoni V, Schiavello E, Diletto B, Pecori E, Gandola L, Massimino M.

5th International CNS Germ Cell Tumors Symposium. Columbus, US. 2017

"Pre-conization Human Papillomavirus Genotype influences the risk of cervical dysplasia recurrence/persistence: developing a predictive model".

Bogani G, Recalcati D, Martinelli F, Mauro S, Chiappa V, Indini A, Ditto A, Lorusso D, Raspagliesi F.

31st International Papillomavirus Conference. Cape Town, SA. 2017

"Should we modify current FIGO staging system for cervical cancer? The importance of surgical staging".

Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Recalcati D, Indini A, Lorusso D, Raspagliesi F.

31st International Papillomavirus Conference. Cape Town, SA. 2017

"New emerging Human Papilloma virus types in the era of nonavalent vaccination".

Bogani G, Recalcati D, Martinelli F, Ditto A, Signorelli M, Indini A, Lorusso D, Raspagliesi F.

31st International Papillomavirus Conference. Cape Town, SA. 2017

"Pretreatment human Papillomavirus (HPV) infection predicts the risk of recurrence/progression in patients with high-grade vaginal intraepithelial neoplasia".

Bogani G, Recalcati D, Martinelli F, Chiappa V, Signorelli M, Indini A, Ditto A, Lorusso D, Raspagliesi F.

31st International Papillomavirus Conference. Cape Town, SA. 2017

"Baseline LDH serum level as predictive value of activity in patients treated with anti-PD1 and PDL-1 monoclonal antibodies".

Cona MS, Torri V, Garassino MC, Di Nicola M, Del Vecchio M, Niger M, Indini A, Signorelli D, Cresta S, Damian S, Duca M, De Braud F.

American Association for Cancer Research (AACR) Annual Meeting. New Orleans, US. 2016

"The role of LDH as predictive marker of activity in patients with solid tumors treated with anti PD-1 and PDL-1 monoclonal antibodies".

Cona MS, Torri V, Garassino M, Di Nicola M, Del Vecchio, Cresta S, Signorelli D, Damian S, Duca M, Indini A, M, Niger M, De Braud F.

14th International Congress on Targeted Anticancer Therapies (TAT 2016). Washington, US. 2016

"ALK and ROS-1 status: a retrospective analysis in solid tumors"

Cona MS, Duca M, Testi A, Cresta S, Dotti K, Indini A, Signorelli D, Pelosi G, De Braud F, Damian S.

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics meeting. Boston, US. 2015

"Druggable aberrations in solid tumors: an overview on ALK and ROS-1 status"

Cona MS, Indini A, Cresta S, Testi A, Signorelli D, Garassino MC, Sinno V, Sesana S, Pelosi G, De Braud F, Damian S.

XVII Associazione Italiana di Oncologia Medica (AIOM) National Congress. Roma, Italia. 2015

"Dysthyroidism during immune checkpoints inhibitors treatment: toxicity or something more?"

Signorelli D, Cona MS, Lo Russo G, Proto C, Vitali M, Macerelli M, Agustoni F, Indini A, Platania M, Zilembo N, Garassino MC, Di Guardo L, Del Vecchio M, Magni M, Sinno V, Seregni E, Di Nicola M, De Braud F.

XVII Associazione Italiana di Oncologia Medica (AIOM) National Congress. Roma, Italia. 2015

"Long-term Responses In Metastatic Melanoma Patients treated with Vemurafenib".

Di Guardo L, Pilla L, Colonna V, Vetrano I, Sparacio E, de Braud F, Indini A, Cimminiello C, Del Vecchio M.

11th International Congress, Society for Melanoma Research Congress (SMR). Zurich, Switzerland. 2014

"In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document."

Milan, June 12th 2025

A handwritten signature in black ink, appearing to be 'De Braud'.